A Quantitative Systems Pharmacology Consortium Approach to Managing Immunogenicity of Therapeutic Proteins
Andrzej Kierzek(University of Surrey), Piet H. van der Graaf(Pfizer (United Kingdom)), Craig J. Thalhauser(Bristol-Myers Squibb (Sweden)), Jatin Narula(Pfizer (United States)), Hiroyuki Sayama(Astellas Pharma (Japan)), Jochem Gokemeijer(Bristol-Myers Squibb (Germany)), Hannah M. Jones(Texas Tech University), Isabel Figueroa(Merck & Co., Inc., Rahway, NJ, USA (United States)), Maciej J. Swat(Simcyp (United Kingdom)), Rong Deng(IGM Biosciences (United States)), Valerie Quarmby, Marjoleen Nijsen(AbbVie (United States)), Vijayalakshmi Chelliah, Lian Zhou(Eli Lilly (United States)), Thierry Lavé(Roche (Switzerland)), Sophie Tourdot(Pfizer (United States)), J. Cory Kalvass(AbbVie (United States)), Sachiko Yokoo(Astellas Pharma (Japan)), Kapil Gadkar(Sea Turtle Conservancy), Abhishek Gulati(Astellas Pharma (United States)), Tarek A. Leil(Children's Hospital of Philadelphia), Ben G. Small, Timothy P. Hickling(Roche (Switzerland)), Geertruida M. Veldman(AbbVie (United States)), Renu Singh Dhanikula(Bristol-Myers Squibb (United States)), Xiaoying Chen(Next Generation Technology (United States)), Mario Giorgi, Akihiro Yamada(Astellas Pharma (Japan)), Michael L. Walker, Andrea Ferrante(Versiti Blood Center of Wisconsin), Jan‐Stefan van der Walt(Eli Lilly (United Kingdom)), Neil Benson(Pfizer (United Kingdom)), Benjamin Ribba(Roche (Switzerland)), K. Varsha Mohan(AbbVie (United States)), Gemma L. Dickinson(Eli Lilly (United States))
Cited by 34
Related Papers
Therapeutic bispecific antibodies cross the blood-brain barrier in nonhuman primates
|Science Translational Medicine|2014|373
SBML Level 3: an extensible format for the exchange and reuse of biological models
|Molecular Systems Biology|2020|306
Addressing Safety Liabilities of TfR Bispecific Antibodies That Cross the Blood-Brain Barrier
|Science Translational Medicine|2013|267